Dan H. Barouch
A5054247332- HIV Research and Treatment
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- COVID-19 Clinical Research Studies
- vaccines and immunoinformatics approaches
- T-cell and B-cell Immunology
- Herpesvirus Infections and Treatments
- HIV/AIDS drug development and treatment
- Monoclonal and Polyclonal Antibodies Research
- HIV/AIDS Research and Interventions
- Virology and Viral Diseases
- Animal Virus Infections Studies
- CAR-T cell therapy research
- Viral gastroenteritis research and epidemiology
- Mosquito-borne diseases and control
- Viral Infections and Vectors
- SARS-CoV-2 detection and testing
- Cytomegalovirus and herpesvirus research
- Vaccine Coverage and Hesitancy
- Viral Infections and Outbreaks Research
- Viral Infectious Diseases and Gene Expression in Insects
- Long-Term Effects of COVID-19
- Viral Infections and Immunology Research
Beth Israel Deaconess Medical Center
2016-2025
Harvard University
2016-2025
Ragon Institute of MGH, MIT and Harvard
2015-2024
Hadassah Medical Center
2004-2024
Massachusetts General Hospital
2021-2024
New York Academy of Sciences
2023
John Wiley & Sons (Germany)
2023
Moss Landing Marine Laboratories
2023
Hudson Institute
2023
Concord Consortium
2020-2022
Identification and characterization of antigen-specific T lymphocytes during the course an immune response is tedious indirect. To address this problem, peptide-major histocompatability complex (MHC) ligand for a given population cells was multimerized to make soluble peptide-MHC tetramers. Tetramers human lymphocyte antigen A2 that were complexed with two different immunodeficiency virus (HIV)-derived peptides or peptide derived from influenza A matrix protein bound peptide-specific...
BackgroundThe Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in prefusion-stabilized conformation.MethodsIn an international, randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned adult participants 1:1 ratio to receive single dose of (5×1010 viral particles) or placebo. The primary end points were efficacy against moderate...
The ongoing pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome 2 (SARS-CoV-2), a major threat to global health1 and the medical countermeasures available so far are limited2,3. Moreover, we currently lack thorough understanding mechanisms humoral immunity SARS-CoV-24. Here analyse large panel human monoclonal antibodies that target spike (S) glycoprotein5, identify several exhibit potent neutralizing activity fully block receptor-binding...
Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding full-length and stabilized SARS-CoV-2 spike protein.In this multicenter, placebo-controlled, phase 1-2a trial, we randomly assigned healthy adults between ages 18 55 years (cohort 1) those 65 age...
The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome 2 (SARS-CoV-2) has made the development of a vaccine top biomedical priority. In this study, we developed series DNA candidates expressing different forms SARS-CoV-2 spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals humoral cellular immune responses, including neutralizing antibody titers at levels comparable to those found convalescent humans macaques infected...
With accumulating evidence indicating the importance of cytotoxic T lymphocytes (CTLs) in containing human immunodeficiency virus–1 (HIV-1) replication infected individuals, strategies are being pursued to elicit virus-specific CTLs with prototype HIV-1 vaccines. Here, we report protective efficacy vaccine-elicited immune responses against a pathogenic SHIV-89.6P challenge rhesus monkeys. Immune were elicited by DNA vaccines expressing SIVmac239 Gag and 89.6P Env, augmented administration...
An understanding of protective immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global disease 2019 (COVID-19) pandemic. A key unanswered question whether infection with SARS-CoV-2 results in against reexposure. We developed a rhesus macaque model observed that macaques had high viral loads upper lower tract, humoral cellular immune responses, pathologic evidence pneumonia. After initial...
We measured plasma and/or serum antibody responses to the receptor-binding domain (RBD) of spike (S) protein SARS-CoV-2 in 343 North American patients infected with (of which 93% required hospitalization) up 122 days after symptom onset and compared them 1548 individuals whose blood samples were obtained prior pandemic. After setting seropositivity thresholds for perfect specificity (100%), we estimated sensitivities 95% IgG, 90% IgA, 81% IgM detecting between 15 28 onset. While median time...
Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetal microcephaly. The development of safe effective ZIKV vaccine therefore an urgent global health priority. Here we demonstrate that three different platforms protect against challenge rhesus monkeys. A purified inactivated induced ZIKV-specific neutralizing antibodies completely protected monkeys strains from both Brazil Puerto Rico. Purified immunoglobulin vaccinated also...
ABSTRACT Recombinant adenovirus serotype 5 (rAd5) vector-based vaccines are currently being developed for both human immunodeficiency virus type 1 and other pathogens. The potential limitations associated with rAd5 vectors, however, have led to the construction of novel rAd vectors derived from rare Ad serotypes. Several already been described, but a detailed comparison multiple subgroups B D has not previously reported. Such is critical selecting optimal advancement into clinical trials....
REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce risk hospitalization or death among high-risk persons with coronavirus disease 2019 (Covid-19). Whether subcutaneous prevents severe acute respiratory syndrome 2 (SARS-CoV-2) infection subsequent Covid-19 in at high for because household exposure person SARS-CoV-2 is unknown. We randomly assigned, 1:1 ratio, participants (≥12 years age) who were...